553 related articles for article (PubMed ID: 17071065)
1. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
2. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study.
Sun H; Pang KS
Drug Metab Dispos; 2008 Jan; 36(1):102-23. PubMed ID: 17932224
[TBL] [Abstract][Full Text] [Related]
3. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2007 Dec; 32(4-5):261-70. PubMed ID: 17890067
[TBL] [Abstract][Full Text] [Related]
4. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
5. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
6. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
7. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
8. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
9. Investigation of vesicle electrokinetic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drug candidates.
Pascoe RJ; Masucci JA; Foley JP
Electrophoresis; 2006 Feb; 27(4):793-804. PubMed ID: 16411277
[TBL] [Abstract][Full Text] [Related]
10. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Rouquayrol M; Gaucher B; Roche D; Greiner J; Vierling P
Pharm Res; 2002 Nov; 19(11):1704-12. PubMed ID: 12458677
[TBL] [Abstract][Full Text] [Related]
11. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
12. Studies of intestinal permeability of 36 flavonoids using Caco-2 cell monolayer model.
Tian XJ; Yang XW; Yang X; Wang K
Int J Pharm; 2009 Feb; 367(1-2):58-64. PubMed ID: 18848870
[TBL] [Abstract][Full Text] [Related]
13. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
14. The constituents of Cibotium barometz and their permeability in the human Caco-2 monolayer cell model.
Wu Q; Yang XW
J Ethnopharmacol; 2009 Sep; 125(3):417-22. PubMed ID: 19635547
[TBL] [Abstract][Full Text] [Related]
15. Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model.
Zidan AS; Spinks CB; Habib MJ; Khan MA
J Liposome Res; 2013 Dec; 23(4):318-26. PubMed ID: 23915251
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
17. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
[TBL] [Abstract][Full Text] [Related]
18. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
19. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
Usansky HH; Sinko PJ
J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
[TBL] [Abstract][Full Text] [Related]
20. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates.
Masungi C; Mensch J; Van Dijck A; Borremans C; Willems B; Mackie C; Noppe M; Brewster ME
Pharmazie; 2008 Mar; 63(3):194-9. PubMed ID: 18444507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
